Core Insights - The study indicates that SUBLOCADE, an extended-release buprenorphine injection, may significantly reduce staff time and associated costs in jails and prisons compared to other medications for opioid use disorder (MOUD) [1][2][3] Group 1: Cost Impact Model Findings - The model estimates that using monthly injectable buprenorphine requires fewer staff hours than other MOUD treatments, with reductions of 318 hours compared to methadone, 747 hours compared to oral buprenorphine, 192 hours compared to weekly extended-release buprenorphine, and 6 hours compared to extended-release naltrexone [7] - The estimated monthly cost savings from reduced staff time range from $23 to $22,148, with the largest savings resulting from the elimination of daily observed dosing and patient escorts [7] Group 2: Staffing Challenges in Correctional Facilities - Correctional facilities are facing ongoing staffing constraints as the demand for MOUD continues to grow, with nearly half of U.S. jails and prisons citing staffing as a primary barrier to providing MOUD [2][3] - The findings suggest that monthly injectable buprenorphine can alleviate the dosing burden and staff involvement, allowing facilities to operate more efficiently while expanding access to evidence-based care [2][3] Group 3: Study Background and Limitations - The study was funded by Indivior and conducted in collaboration with Veradigm and researchers from the University of Kentucky College of Medicine [4] - Limitations of the study include the exclusion of medication acquisition costs and some administration times based on assumptions due to a lack of available data [3]

Core Insights - Indivior Pharmaceuticals announced findings from a study indicating that adherence to SUBLOCADE is linked to significantly lower healthcare utilization and costs for patients with opioid use disorder (OUD) compared to other medications and nonadherent patients [1][5][8] Group 1: Study Findings - The study published in Frontiers in Public Health shows that patients adhering to SUBLOCADE had 42% lower adjusted non-MOUD medical costs, amounting to $15,017 less annually per patient compared to those adhering to other forms of MOUD [8][9] - Patients on SUBLOCADE experienced the lowest rates of inpatient admissions, emergency department visits, and detoxification services, highlighting the treatment's effectiveness in reducing acute healthcare needs [4][8] - The study reinforces the importance of evaluating OUD treatment based on total healthcare costs, suggesting that long-acting therapies like SUBLOCADE can lead to system-wide savings while improving patient care continuity [6][9] Group 2: Treatment Context - SUBLOCADE is indicated for the treatment of moderate to severe OUD and should be part of a comprehensive treatment plan that includes counseling and psychosocial support [10] - The study's findings contribute to the growing evidence that long-acting injectable buprenorphine treatments support sustained engagement in care and reduce costly acute healthcare use [2][5] - Indivior is positioned as a leader in long-acting injectable treatments for OUD, focusing on evidence-based treatment and advancing the understanding of OUD as a chronic but treatable condition [22]

Indivior, Powering Recovery, Renewing Hope. Investor Presentation February 26, 2026 IMPORTANT CAUTIONARY STATEMENT REGARDING FORWARD- LOOKING STATEMENTS This presentation contains certain statements that are forward-looking. Forward-looking statements include, among other things, express and implied statements regarding: the Company's financial guidance for 2026, including total net revenue, SUBLOCADE® net revenue, non-GAAP gross margin, non-GAAP operating expenses, adjusted EBITDA, and cash flow from opera ...

Summary of Indivior Conference Call Company Overview - **Company**: Indivior - **Market Cap**: $4 billion - **Annual Turnover**: Approximately $1.2 billion - **Industry**: Opioid Use Disorder Treatment Key Points Q3 Results and Financial Performance - Indivior reported a strong Q3 performance, marking the second consecutive quarterly beat since the new CEO's appointment, with stock reaching a seven-year high [1][2] - The company raised its four-year guidance, attributing this to better-than-expected performance in Sublocade and modest erosion of Suboxone [2][3] - A significant cost-saving initiative is expected to yield $150 million in savings next year, exceeding most expectations [2][3] Product Performance: Sublocade - Sublocade, a first-in-class long-acting injectable for opioid use disorder, has seen a 10% growth this year, up from flat growth at the beginning of the year [3][4] - The product has been used in over 350,000 patients, indicating a strong market presence [4] - Indivior's action agenda focuses on improving commercial execution and enhancing product awareness, contributing to Sublocade's momentum [4][5] Market Opportunity - There are approximately 9 million individuals misusing opioids, with only 2 million receiving treatment with buprenorphine, highlighting a significant growth opportunity for long-acting injectables [3][4] - Current unprompted patient awareness of Sublocade is only 4%, indicating substantial room for growth through consumer education campaigns [9][10] Market Share and Competitive Landscape - Indivior holds a 75% market share for Sublocade, with competitors holding around 30% [20][21] - The company emphasizes the importance of increasing long-acting injectable penetration rather than merely focusing on market share percentages [22][23] Suboxone Performance - Suboxone continues to generate approximately $200 million in revenue, maintaining a 25% share of the film market despite the presence of four generics [24][25] - The stability of generic pricing has contributed positively to Suboxone's revenue profile [25][26] Cost Management and Operational Efficiency - Indivior plans to reduce operational expenses to approximately $450 million next year, with a focus on essential investments for Sublocade [28][29] - The company has reduced headcount by over 30% and discontinued non-essential sales and marketing efforts [29][30] Future Growth and Pipeline - Indivior is preparing to enter a phase of accelerated growth starting January 1, 2026, with expectations of increased revenue from Sublocade [15][17] - The company is exploring new growth drivers and remains open to acquiring commercial-stage assets with potential revenue of at least $200 million [36][37] - Upcoming phase two trials for new products, including a three-monthly formulation and an orexin-1 antagonist, are fully funded and will be evaluated based on data outcomes [45][46] Capital Allocation and Shareholder Returns - Indivior has a history of share buybacks, having repurchased $400 million worth of shares at an average price of $14.60 [42][41] - The company is currently focused on operational stability and growth before considering further capital returns to shareholders [41][42] Conclusion Indivior is positioned for growth in the opioid use disorder market, with a strong focus on its flagship product Sublocade. The company is implementing strategic cost-saving measures while preparing for future growth opportunities through product development and market expansion.

Core Insights - Ensysce Biosciences, Inc. (ENSC) stock experienced a nearly 100% increase in value, with significant trading volume surpassing the average of 81.23K shares [1] - The company received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent related to Enzyme-Cleavable Methadone Prodrugs, which includes claims for both composition and methods of use [1] Group 1: Product Development and Clinical Trials - PF9001, the medication associated with the new patent, aims to provide a safer treatment for opioid use disorder (OUD) utilizing Ensysce's TAAP and MPAR technologies for abuse deterrence and overdose protection [2] - Methadone has been traditionally used for OUD, but its application has been limited due to concerns about cardiac side effects and overdose risks [3] - Ensysce has developed PF9001, which shows reduced cardiotoxicity and validates the MPAR technology for overdose protection, with indications of a prolonged effect from once-daily dosing [3] Group 2: Clinical Trial Results - The National Institute on Drug Abuse supported the research for the patent, and Ensysce completed Part 1 of its second clinical trial for PF614-MPAR, which demonstrated effective overdose protection while relieving severe pain [4] - The trial confirmed that a 100 mg dosage of PF614-MPAR provides overdose protection when doses exceed the prescribed amount, showing reduced maximum oxycodone release compared to PF614 alone [5] - Safety data from the trial indicated no unexpected adverse events, and the study will continue to evaluate food effects and repeat dosing [6] Group 3: Financial Activities - Ensysce Biosciences announced a registered direct offering of approximately $1.1 million in March, issuing 315,188 shares at a price of $3.49 per share [7] - Following the news, ENSC stock rose by 96.30%, reaching a price of $3.67 [7]